Briefing
Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.
MRD-window ctDNA positivity was 8.1% (34/420) in stage II and 24.9% (126/505) in stage III, with DFS HR 10.4 and 10.1, respectively (both P<0.0001). Combined 24-month DFS was 91.7% if MRD-negative vs 41.4% if MRD-positive. During surveillance, conversion to ctDNA-positive was associated with markedly worse DFS in both observation and ACT-treated patients (stage II observation HR 34.9; stage III ACT HR 54.6).
- n: 1,001 in the sub-cohort; 625 (62.4%) received ACT; MRD-window results in 420 stage II and 505 stage III
- Assay: Signatera (tumor-informed)